Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic Melanoma

Open-label Pharmacokinetic Trial of Aldesleukin (Rh-Interleukin-2 [IL-2]) Administered Intravenously to Subjects With Metastatic Renal Cell Carcinoma or Metastatic Melanoma With Immunologic Correlative Studies

This study evaluated the pharmacokinetics of aldesleukin in participants with metastatic renal cell cancer or metastatic melanoma.

Inclusion criteria:

• Performance Status Eastern Cooperative Oncology Group: 0 or 1.
• Adequate organ function.

Exclusion criteria:

• Pregnancy or lactation.
• Prior treatment with any form of IL-2.
• Organ transplant. Other protocol-defined inclusion/exclusion criteria may apply